Association of the British Pharmaceutical Industry (ABPI)
Race against time: Looking at the latest Brexit developments and their impact on pharma
With recent plans announced by the UK’s prime minister to remain part of the EMA, which would be favourable for many in the pharma industry, I will look at these developments as well as how they will impact industry and the reactions from leaders more
The top five tweets: From the ‘secret payments’ to asthma — what interested EPM readers this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more
ABPI responds to the investigation by The Times into ‘secret payments’ by pharma companies
The ABPI has responded to an investigation performed by The Times into ‘secret payments’ worth millions made by two major pharma companies to healthcare professionals (HCPs) and organisations (HCOs) more
Cautious optimism on Brexit progression: Pharma, biotech & manufacturing industries give their thoughts
As the guidelines for the negotiations of future relations between the EU and the UK are approved, allowing the progression of Brexit talks, pharma, biotech and manufacturing industry leaders give their opinions on the transition. more
UK’s pharma and biotech support new Health and Social Care Committee report into Brexit
The associations representing the UK’s pharma and biotech industries have announced their support of the recently published findings of the new Health and Social Care Committee report into Brexit. more
New national standards launch to improve UK public involvement in research
A new set of national standards have been launched at the 2018 Patients First conference and the Involving People Network Annual Meeting 2018 that are designed to improve the quality and consistency of public involvement in research across the UK. more
The top five tweets: From the Med-Tech Expo to International Women’s Day — what did EPM readers enjoy this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more
ABPI launches plan to encourage more young women into STEM careers on International Women's Day
The Association of the British Pharmaceutical Industry (ABPI) has launched a plan to help encourage young scientists to consider a career in STEM. more
UK-wide life science leaders welcome new version of mCTA, notes ABPI
A new version of the model Clinical Trials Agreement (mCTA), aimed at speeding up clinical trials and medicines research, has been welcomed by life science leaders across the whole of the UK, according to the ABPI more
Making a difference in rare diseases: A pharma perspective
Today (28 February) is Rare Disease Day 2018, where companies, organisations, charities and governments raise awareness of rare diseases and the development of the various treatments and cures. more
ABPI expresses concerns over CEMIPP recommendations
The Association of the British Pharmaceutical Industry (ABPI) has expressed concern over the recent recommendations set out in the consultation on the CEMIPP, which it states will negatively affect the nation’s health. more
ABPI reaffirms position on Brexit in reaction to MHRA’s update
The Association of the British Pharmaceutical Industry (ABPI) has issued its reaction to the publication of the Medicines and Healthcare products Regulatory Agency’s (MHRA) update to pharma companies on preparing for Brexit. more
The top five tweets: From Brexit to Huntington’s disease — what did EPM readers enjoy this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more
ABPI research shows a six-fold increase in CVC investment in UK biotech
The Association of the British Pharmaceutical Industry (ABPI) has released research showing that the amount of capital invested alongside corporate venture capital (CVC) in UK biotech increased six-fold between 2010 and 2015. more
BIA and ABPI release research on impact of Brexit, highlighting the need to safeguard public health
To coincide with the House of Commons Health Select Committee hearing evidence on ‘Brexit: the regulation of medicines, medical devices and substances of human origin’, the ABPI and the BIA release research on impact of UK’s exit from Europe more
Industry reacts to Brexit progression announcement
As Brexit moves to the next phase, thanks to ‘sufficient progress’ being made in phase one of the negotiations as announced by the European Commission president Jean-Claude Juncker and prime minister Theresa May, some industry bodies welcome the news more
Written evidence published on the impact Brexit may have on the pharma industry
Written evidence has been published by the Business, Energy and Industrial Strategy Committee, suggesting the impact Brexit may have on the pharmaceutical industry. more
Scottish pharma may drive long-term sustainable growth, notes report
Research from the Fraser of Allander Institute (FAI), mapping out the economic contribution of Scotland’s pharmaceutical sector, has been released by the Association of the British Pharmaceutical Industry (ABPI) Scotland. more
Autumn budget 2017: Reactions from pharma and industry on some of the key announcements
Following the chancellor’s autumn budget announcement, we provide a brief round-up of the key points and some of the reactions from the pharma and industry leaders. more
The votes are in... the EMA will be located in Amsterdam
The results of the vote for the relocation of the European Medicines Agency (EMA) have been revealed, its new location will be Amsterdam. Here are some key industry responses… more
